Form 4: FibroGen CEO Wettig Thane Reports Stock Transaction
SEC Form 4 Filing
CEO Wettig Thane reports a transaction involving FibroGen stock, including shares withheld for tax obligations.
Summary
- On March 22, 2024, FibroGen CEO Wettig Thane reported a transaction involving the company's common stock.
- 782 shares were disposed of to satisfy a tax obligation at a price of $2.58 per share.
- Following the transaction, Wettig Thane directly owns 469,396 shares of FibroGen common stock.
- Wettig Thane also indirectly owns 1,000 shares through a spouse.
Sentiment
Score: 5
Explanation: This is a neutral report of a stock transaction related to tax obligations. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure related to insider trading and is required by the SEC.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/22/2024 | Date of stock transaction |
| 03/25/2024 | Date of signature for the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.